Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 17/20 | 0.68 |
| ▸ | MAPK12 | P53778 | 17/20 | 0.68 |
| ▸ | MAPK11 | Q15759 | 17/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6585407 | 1.00 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL11175120 | 0.82 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4587383 | 0.81 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL4913956 | 0.81 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL8860326 | 0.79 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL4915403 | 0.77 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL8860433 | 0.76 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL11083061 | 0.76 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1387655 | 0.76 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL8860439 | 0.75 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0993456-B1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | NOVARTIS AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| EP-1396491-A2 | 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors | Novartis AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| US-6300347-B1 | FOR THERAPY OF TUMOR NECROSIS FACTOR AND INTERLEUKIN-1 MEDIATED DISEASES SUCH AS RHEUMATOID ARTHRITIS AND DISEASES OF BONE METABOLISM, E.G. OSTEOPOROSIS | NOVARTIS AG (CH) | 2001-10-09 | — | — | US | disclosed |
| EP-0993456-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | Novartis AG (CH) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999001449-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | NOVARTIS AG (CH) | 1999-01-14 | — | — | WO | disclosed |